Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02867384 · ClinicalTrials.gov registry record · Phase 2
Obinutuzumab in cGVHD After Allogeneic Peripheral Blood Stem Cell Transplantation
A Phase 2 study of Graft Vs Host Disease, sponsored by Dana-Farber Cancer Institute.
- Completed
- Registry status
- Phase 2
- Development phase
- 181
- Enrollment target
- 5
- Study locations
NCT02867384: Completed Phase 2 study of Graft Vs Host Disease, sponsored by Dana-Farber Cancer Institute.
NCT02867384 is a Phase 2 study of Graft Vs Host Disease that has completed, run by Dana-Farber Cancer Institute. The registered enrollment target is 181 participants, above the 133-participant average among 36 other Graft Vs Host Disease trials with a reported enrollment target (36% higher). The trial reports 5 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02867384, a Phase 2 study of Graft Vs Host Disease, has completed, sponsored by Dana-Farber Cancer Institute.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 181 participants
- Enrollment target
- 5
- Study locations
Study Summary
This research study is studying a drug called obinutuzumab as a means of preventing chronic Graft vs. Host Disease (cGVHD).
Primary Outcome
Corticosteroid-requiring cGVHD is defined as the percentage of participants who develop chronic Graft Versus Host Disease cGVHD requiring treatment with corticosteroids within the first year following Hematopoietic Cell Transplantation HCT.
Conditions Studied
Interventions
- DRUG Obinutuzumab
- DRUG Placebo
Study Locations (5)
Massachusetts
- Massachusetts General Hospital - Boston
- Dana Farber Cancer Institute - Boston
California
- Stanford University - Palo Alto
Minnesota
- Masonic Cancer Center - Minneapolis
Utah
- Huntsman Cancer Institute - Salt Lake City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 181 participants |
| Start Date | 2016-11-29 |
| Est. Completion | 2024-11-14 |
| Phase | Phase 2 |
What the finished NCT02867384 record still lists
NCT02867384 is an interventional study that assigns participants to a tested intervention. The registered 181 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 36 other Graft Vs Host Disease trials with a reported enrollment target (36% higher).
The record links to 1 condition, with Graft Vs Host Disease appearing as the primary indexed condition, and to 2 interventions - of which Obinutuzumab is the first listed.
NCT02867384 lists 5 locations in 4 states (Massachusetts, California, Minnesota).
Frequently Asked Questions
What is clinical trial NCT02867384 about?
NCT02867384 is a clinical study titled "Obinutuzumab in cGVHD After Allogeneic Peripheral Blood Stem Cell Transplantation". This research study is studying a drug called obinutuzumab as a means of preventing chronic Graft vs. Host Disease (cGVHD).
What is the current status of trial NCT02867384?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 181 participants. The study started on 2016-11-29. Estimated completion is 2024-11-14.
What conditions does trial NCT02867384 study?
This clinical trial studies the following conditions: Graft Vs Host Disease.
What interventions are being tested in trial NCT02867384?
The interventions under investigation include: Obinutuzumab (DRUG), Placebo (DRUG).
Who is sponsoring clinical trial NCT02867384?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02867384 being conducted?
This trial has 5 study locations across California, Massachusetts, Minnesota, Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Graft Vs Host Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02867384's enrollment target sits among peer trials
181 7th of 36 higher than 30 of 36 other Graft Vs Host Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Graft Vs Host Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Extended vs Short-term Abatacept Dosing for Graft Versus Host Disease Prophylaxis
RECRUITING · Phase 2
-
A Study of Belumosudil in People at Risk of Developing Graft-Versus-Host Disease After a Stem Cell Transplant
RECRUITING · Phase 2
-
Vitamin A Supplementation in Allogeneic Stem Cell Transplantation.
RECRUITING · Phase 2
-
Cyclophosphamide, Abatacept, and Tacrolimus for the Prevention of GvHD
ACTIVE NOT RECRUITING · Phase 2
-
Nonmyeloablative Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Sickle Cell Disease and Beta-thalassemia in People With Higher Risk of Transplant Failure
ACTIVE NOT RECRUITING · Phase 2
-
RGI-2001 for the Prevention of Acute Graft-vs-Host Disease in Subjects Following Allogeneic Hematopoietic Stem Cell Transplantation
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04578392 · 181 participants · NA
MeSenteric SpAring Versus High Ligation Ileocolic Resection for the Prevention of REcurrent Crohn's DiseaSe (SPARES)
- NCT05597891 · 181 participants · NA
Endovascular Engineering ENGULF Study
- NCT03897998 · 182 participants · Phase 2
Neural Correlates of Hypoalgesia Driven by Observation
- NCT04300556 · 182 participants · Phase 1
A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI